← Leaderboards
George Ueda
University Of Washington
$436,804
Attributed
$436,804
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $308.9K · FY2021–22$500K$375K$250K$125K$0
'21
'22
Funding mix
By agency
NIH$436,804 · 1
By mechanism
R21$436,804 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- David Veesler$16,345,259
- Robert K Ernst$6,785,080
- David Baker$22,630,205
- Patrick S. Stayton$27,743,768
- Margaret Lind$654,045
Others in their field
Other Emerging Leaders on “Clinical Medicine”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$324,392,296
- Lynn Briscoe · Leidos Biomedical Research, Inc.$111,781,421
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Prasant Mohapatra · University Of California At Davis$52,567,812
Research focus
Clinical MedicineClinical Trials2019-NcovAdaptive ImmunityAcuteAgonistAce2AlveolarAlveolar EpitheliumAnimal ModelAppropriate DoseBindingBiological AvailabilityBloodBlood CirculationAirway EpitheliumBypassC57bl/6 MouseCapillary PermeabilityCell CommunicationCellsCessation Of LifeClinicContainment
Grant awards (2)
De Novo Designed Protein Nanoparticle Agonists Targeting the Tie2 Receptor for the Treatment of ARDS and Sepsis in Patients with COVID-19$127,929
R21 · FY2022 · AI · contact PI
De Novo Designed Protein Nanoparticle Agonists Targeting the Tie2 Receptor for the Treatment of ARDS and Sepsis in Patients with COVID-19$308,875
R21 · FY2021 · AI · contact PI